JA-Kathy Mngadi - The Aurum Institute

Pharmacokinetics and predicted neutralisation coverage of VRC01 in HIV-uninfected participants of the Antibody Mediated Prevention (AMP) trials

Huang, Y., Naidoo, L., Zhang, L., Carpp, L.N., Rudnicki, E., Randhawa, A., Gonzales, P., McDermott, A., Ledgerwood, J., Lorenzo, M.M.G. and Burns, D., 2021. Pharmacokinetics and predicted neutralisati...
Aurum's Kathy Mngadi on Metro FM's The Kings Suite

...
Infusion Reactions After Receiving the Broadly Neutralizing Antibody VRC01 or Placebo to Reduce HIV-1 Acquisition

Takuva, S., Karuna, S.T., Juraska, M., Rudnicki, E., Edupuganti, S., Anderson, M., De La Grecca, R., Gaudinski, M.R., Sehurutshi, A., Orrell, C. and Naidoo, L., 2022. Infusion Reactions After Receivi...
Annual Tuberculosis Preventive Therapy for Persons With HIV Infection

Churchyard, G., Cárdenas, V., Chihota, V., Mngadi, K., Sebe, M., Brumskine, W., Martinson, N., Yimer, G., Wang, S.H., Garcia-Basteiro, A.L. and Nguenha, D., 2021. Annual tuberculosis preventive thera...
Immune correlates analysis of the Imbokodo (HVTN 705/HPX2008) efficacy trial of a mosaic HIV-1 vaccine regimen evaluated in Southern African people assigned female sex at birth: a two-phase case-control study.

Kenny A, van Duijn J, Dintwe O, Heptinstall J, Burnham R, Sawant S, Zhang L, Mielke D, Khuzwayo S, Omar FL, Stanfield-Oakley S, Keyes T, Dunn B, Goodman D, Fong Y, Benkeser D, Zou R, Hural J, Hyrien O...
Mosaic HIV-1 vaccine regimen in southern African women (Imbokodo/HVTN 705/HPX2008): a randomised, double-blind, placebo-controlled, phase 2b trial.

Gray GE, Mngadi K, Lavreys L, Nijs S, Gilbert PB, Hural J, Hyrien O, Juraska M, Luedtke A, Mann P, McElrath MJ, Odhiambo JA, Stieh DJ, van Duijn J, Takalani AN, Willems W, Tapley A, Tomaras GD, Van Ho...
Safety and immunogenicity of a subtype C ALVAC-HIV (vCP2438) vaccine prime plus bivalent subtype C gp120 vaccine boost adjuvanted with MF59 or alum in healthy adults without HIV (HVTN 107): A phase 1/2a randomized trial.

Moodie Z, Andersen-Nissen E, Grunenberg N, Dintwe OB, Omar FL, Kee JJ, Bekker LG, Laher F, Naicker N, Jani I, Mgodi NM, Hunidzarira P, Sebe M, Miner MD, Polakowski L, Ramirez S, Nebergall M, Takuva S,...

Pharmacokinetics and predicted neutralisation coverage of VRC01 in HIV-uninfected participants of the Antibody Mediated Prevention (AMP) trials

Aurum's Kathy Mngadi on Metro FM's The Kings Suite

Infusion Reactions After Receiving the Broadly Neutralizing Antibody VRC01 or Placebo to Reduce HIV-1 Acquisition

Annual Tuberculosis Preventive Therapy for Persons With HIV Infection

Immune correlates analysis of the Imbokodo (HVTN 705/HPX2008) efficacy trial of a mosaic HIV-1 vaccine regimen evaluated in Southern African people assigned female sex at birth: a two-phase case-control study.

Mosaic HIV-1 vaccine regimen in southern African women (Imbokodo/HVTN 705/HPX2008): a randomised, double-blind, placebo-controlled, phase 2b trial.

Safety and immunogenicity of a subtype C ALVAC-HIV (vCP2438) vaccine prime plus bivalent subtype C gp120 vaccine boost adjuvanted with MF59 or alum in healthy adults without HIV (HVTN 107): A phase 1/2a randomized trial.

Popular Tags

Most Read

Recent Posts